Ritonavir-boosted nirmatrelvir: Difference between revisions
| Line 45: | Line 45: | ||
==Comments== | ==Comments== | ||
* renally dosed eGFR 30-60 then 150 mg/100 mg dosing | * renally dosed eGFR 30-60 then 150 mg/100 mg dosing | ||
*89% reduction in hospitalization or death in high risk population, and 70% reduction in hospitalizations with no deaths in standard risk population. | *89% reduction in hospitalization or death in high risk population, and 70% reduction in hospitalizations with no deaths in standard risk population. | ||
Revision as of 20:21, 18 January 2022
Administration
- Type:
- Dosage Forms:
- Routes of Administration:
- Common Trade Names: Paxlovid
Adult Dosing
COVID
Pediatric Dosing
Special Populations
Pregnancy Rating
Lactation risk
Renal Dosing
- Adult:
- Pediatric:
Hepatic Dosing
- Adult:
- Pediatric:
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
Common
Pharmacology
- Half-life:
- Metabolism:
- Excretion:
Mechanism of Action
Comments
- renally dosed eGFR 30-60 then 150 mg/100 mg dosing
- 89% reduction in hospitalization or death in high risk population, and 70% reduction in hospitalizations with no deaths in standard risk population.
- Many drug interactions
- E.g. Plavix, Phenytoin, Tacrolimus, Tramadol, Statins, Hydro/oxycodone/Codeine, Diazepam/Clonazepam/Alprazolam, Fentanyl, Tamsulosin